ABSTRACT-The effects of 9-amino-1,2,3,4-tetrahydroacridine (tacrine), an active acetylcholinesterase inhibitor, on cycloheximide and basal forebrain (BF) lesion-in duced memory deficit in the water maze and passive avoidance task were investigated. While cycloheximide (1.5 mg/kg, s.c.) produced amnesia in the passive avoidance task, chronic administration of tacrine (1, 3 and 10 mg/kg, once a day for 1 week) im proved the amnesia. BF lesion produced amnesia in both the water maze and passive avoidance tasks. Chronic tacrine (0.1 3 mg/kg, passive avoidance task, or 0.3 mg/kg, water maze task, once a day for 1 week) improved BF lesion-induced amnesia in the passive avoidance and water maze tasks. These results suggest that tacrine may be useful for senile dementia.
Alzheimer's disease is a slowly progressive neuropsychiatric illness of unknown cause, principally characterized by memory deficits. Some specific neurochemical derangements have been observed in the brains of patients with Alzheimer's disease. One of the major changes is a decrease in activity of the enzyme choline acetyltransferase in the cerebral cortex and hippocampus, leading to a degeneration of cholinergic neurons in the basal-forebrain (BF) (1) (2) (3) . The increase in central cho linergic function by the use of anti-cholinester ase drugs to prevent the breakdown of acetyl choline (ACh) constitutes one pharmacological strategy for alleviating cognitive decline in Alzheimer's disease patients.
Recent studies have reported the beneficial effect of tacrine on memory and learning in experimental animals (4) (5) (6) (7) . It has been sug gested that tacrine acts through AChergic sys tems, such as inhibition of ACh esterase (AChE) activity (8) and regulation of ACh re lease (9) . Interestingly, some clinical studies have indicated that tacrine is effective in treat ing Alzheimer's disease (10, 11) . In previous animal experiments, the single high dose of tacrine (1-5 mg/kg) was administered intra peritoneally (i.p.) or subcutaneously (s.c.) (4) (5) (6) (7) . Therefore, to clarify the efficiency of tacrine, the present study investigated the effect of oral, subacute (1 week) administra tion of tacrine at a low dose for clinical trial.
MATERIALS AND METHODS

Animals
Male Kbl Wistar rats (Kitayama Laboratories Co., Ltd., Kyoto, Japan) weighing about 300 g were used. They were given food and water ad libitum and were kept in a regulated en vironment (23 ± 1°C, 50 ± 5% humidity), with a 12 hr light-dark cycle (8 a.m. to 8 p.m.: light).
Drugs
Tacrine was dissolved in distilled water. Cycloheximide (Sigma, St. Louis, MO) was dissolved in a 0.9% saline solution. Ibotenic acid (Sigma) was dissolved in small volume of 0.36 N sodium hydroxide solution, neutralized by 0.36 N hydrochloric acid solution and di luted to the appropriate concentration by 50 mM phosphate-buffer (pH 7.4). Tacrine and cycloheximide were administered p.o. and s.c., respectively. Ibotenic acid was injected into BF.
Surgery
Animals were given pentobarbital (40 mg/kg, i.p., Abbott, U.S.A.) immediately be fore surgery. Bilateral neurotoxic lesions of the BF were produced by injections of ibotenic acid using a 0.5-ul microsyringe in serted into the BF (Bregma: A, 1.5 mm; L, 2.6 mm; H, 8.3 mm) according to the stereo taxic atlas of Paxinos and Watson (12) . Ibotenic acid was infused in a volume of 0.5 ul over 5 min. Bilateral BF lesions were made by injecting ibotenic acid on each side at an interval of 3 days. The injection needle was left in the place for 5 min more to ensure that the drug had diffused away from the needle tip. Sham-operated rats received 50 mM phosphate-buffer in the same way.
Passive avoidance task
The apparatus consisted of two compart ments, one light compartment (25 cm long, 15 cm wide and 15 cm high) and one dark com partment of the same size, connected via a guillotine door (13) . On day 1, just before the acquisition trial, each rat was placed in the light compartment and then allowed to enter the dark compartment; the time taken to do so was recorded in seconds. In the acquisition trial, once the rat entered the dark compart ment, the guillotine door was closed and an electric shock (2.2 mA for 3 sec) was delivered via the grid floor. The animal was then put back into the home cage until the retention trial. The retention trial was carried out 24 hr after the acquisition trial. At that time, we re turned the rat to the light compartment and recorded the time taken to enter the dark compartment (step-through latency, STL). In the screening of tacrine using cycloheximide induced and BF-lesioned models, maximum cut-off latencies of 600 and 300 sec were used, respectively.
Water maze task
A circular water tank (140 cm in diameter, 45 cm in high) was used. A transparent plat form (10 cm in diameter, 28 cm in high) was located in a constant position in the middle of one quadrant inside the tank, equidistant from the center and edge of the pool. The tank was filled with water at approximately 23°C (the platform's top surface being 2 cm below the surface of the water). The pool was located in a large test room, in which there were many cues external to the maze, which were visible from within the pool, and could be used by the rat for spatial orientation. Positions of the cues were kept unchanged throughout the period of training. For each training session, the rat was placed in the water so that it faced the wall of the pool. Each rat started at one of five starting positions, but the sequence of the positions was selected randomly. In each train ing session, the goal latency to escape onto the hidden platform was recorded. If the rat was unable to find the platform within 200 sec, the training session was terminated and a max imum score of 200 sec was assigned. The be havioral trace and the distance of swimming in the water maze were monitored by TV camera and analyzed by computer system (BTA-2A, Muromachi Co., Ltd., Tokyo, Japan).
Experimental schedule
Cycloheximide (1.5 mg/kg, s.c.) was admin istered immediately after training. The dose of cycloheximide used was selected according to previous experiments (13) . Briefly, cyclohex imide failed to produce amnesia at the dose of 1.0 mg/kg and produced more severe side effects at the dose of 3.0 mg/kg. Tacrine (0.3, 1, 3 and 10 mg/kg) was administered once a day for 1 week before training and once be fore the retention trial of the passive avoid ance task. The water maze task was started 2 weeks after the BF lesion, and the administra tion of tacrine was commenced 1 week before the water maze task. The water maze task was carried out one trial a day for 6 days. The rats received tacrine at the doses of 0.1, 0.3, 0.5 and 3 mg/kg, p.o. 30 min before every train ing session of the water maze task. Sham operated animals received distilled water 30 min before every training. The passive avoid ance task was carried out after the water maze task in the BF-lesioned rats. The rats received tacrine (0.1, 0.3, 0.5 and 3 mg/kg, p.o.) 30 min before the acquisition and retention trial of the passive avoidance task.
Assay for choline acetyltransferase (ChAT) activity
ChAT activities in the sham-operated and BF-lesioned groups were assayed. Rats were decapitated 5 days after the last drug adminis tration, and the brain was removed rapidly and dissected into the following regions: the prefrontal cortex, the fronto-parietal cortex and the hippocampus (14) . The tissue was stored at -80°C for assay at a later time. ChAT activity was measured by the method of Fonnum (15) . The tissue was homogenized (4% w/v) in cold 50 mM phosphate-buffer (pH 7.4). Triton X-100 (0.5% v/v) was added to the homogenates to ensure release of en zyme (enzyme solution). A 125-,u1 aliquot of substrate mixture (0.35 mM [3H]-acetyl-Coen zyme A, 4.0 mCi/mmol), 300 mM NaCI, 50 mM phosphate-buffer (pH 7.4), 8 mM choline chloride, 20 mM EDTA, and 0.1 mM physo stigmine was added to 75 ,u l of enzyme solution in a scintillation vial and incubated at 37°C for 30 min. After the incubation, 1 ml of cold 50 mM phosphate-buffer, 0.5 ml of acetonitrile containing 2.5 mg of tetraphenylboron, and 1.5 ml of toluene were added to the scintilla tion vial. The vials were shaken lightly and allowed to sit overnight before counting. Pro tein was measured by the method of Lowry et al. (16) .
Statistical analyses
Data for the water maze task were analyzed by a repeated type of 2 way-analysis of variance (ANOVA), followed by the two tailed Mann-Whitney U-test. Data for the pas sive avoidance task were expressed in terms of medians and interquartile ranges and analyzed using the Kruskal-Wallis test, followed by Mann-Whitney's U-test.
RESULTS
The BF lesion produced aphagia and ataxia for 3 to 5 days after the surgery. These be havioral changes were ameliorated by provid ing water and small amounts of food inside the home cage and did not persist beyond 7 days after surgery. No drug treatment changed the step-through latency in the training of the passive avoidance task ( Table 1) .
Effect of subacute tacrine administration on cycloheximide-induced amnesia in the passive avoidance task (Experiment 1)
As shown in Fig. 1 , the STL of the cyc loheximide (1.5 mg/kg, s.c.)-treated group shortened significantly compared to that of the control group. The shortened STL induced by cycloheximide was significantly reversed by subacute administration of tacrine (1-10 mg/kg) for 1 week (2 = 18.13, P < 0.01).
Effect of subacute tacrine administration on the BF lesion-induced amnesia in the passive avoid ance task (Experiment 2)
As shown in Fig. 2 , ibotenic acid (4 20 fig/rat) significantly shortened STL as com pared with the sham-operated group (X2 = 27.06, P < 0.01).
As shown in Fig. 3 , the shortened STL of the BF lesion (ibotenic acid 12 mg/rat)-group was prolonged by subacute administration of tacrine (0.1, 0.3, 0.5 and 3 mg/kg) for 3 weeks (X2 = 23.69, P < 0.01). The dose-response Table   1 .
Step-through latency on the training of passive avoidance task in drug-treated rats Fig. 1 . Effect of subacute (1 week) administration of tacrine on the cycloheximide-induced amnesia in the rats in the step through passive avoidance task. The columns and the numbers in parentheses show the me dian and interyuartile range, respectively. Overall X' = 18.13, P < 0.01 (Kruskal-Wallis test) . *"P 0.01 vs. vehicle-treated group; #P < 0.05, ##P < (1.(11 vs. cycloheximide-treated group (Mann-Whitney's U test). N = 10 1?. Fig. 2 . Effect of ihotenic acid on acquisition of the step-through passive avoidance task in rats. The col umns and the numbers in parentheses show the median and interquartile range, respectively. Overall X2 = 27.06, P < 0.01 (Kruskal-Wallis test). **P < 0.01 vs. vehicle-treated group (Mann-Whitney's U-test). N = 10. Fig. 3 . Effect of subacute (3 weeks) administration of tacrine on basal forebrain lesion-induced amnesia in rats in the step-through passive avoidance task. The columns and the numbers in parentheses show the me dian and intcrquartile range, respectively. Overall x2 = 23.69, P < 0.01 (Kruskal-Wallis test). **P < 0.01 vs. vehicle-treated group; # P < 0.05, ""P < 0.01 vs. ihotenic acid-treated group (Mann-Whitney's U-test) . N=5-16. curve for tacrine was bell-shaped.
Effect of subacute tacrine administration on the BF lesion-induced amnesia in the water maze task (Experiment 3)
As shown in Fig. 4 , ibotenic acid (4 20 ,ug/rat) significantly extended goal latencies from 2 to 6 sessions in the water maze task, as compared with the sham-operated group [F(4,270) = 12.78, P < 0.011.
As shown in Fig. 5 , 2-weeks subacute ad ministration of tacrine (0.3 mg/ kg) shortened the prolonged goal latency induced by ibotenic acid (12 ,ug/rat) [F(5,252) = 4.35, P < 0.01]. The dose-response curve for tacrine was bell shaped. There was no significant difference between the control and other drug-treatment groups. Effect of subacute tacrine administration on the BF lesion-induced decrease of ChA T activity At the dose used, ibotenic acid significantly decreased the ChAT activity in the anterior occipital cortex (P < 0.05 one-way ANOVA). Tacrine (0.1 0.5 mg/kg) failed to ameliorate the decrease of the ChAT activity (Table 2) .
DISCUSSION
In the present study, cycloheximide induced amnesia in the passive avoidance task. It has usually been interpreted as resulting from an inhibition of the synthesis of cerebral proteins during the critical post-training consolidation period which prevents the manufacture of pro teins necessary for long-term memory (17, 18) . The training-induced elevation in muscarinic receptor density was blocked by cycloheximide administration (19) . We have also reported that cycloheximide decreases the density of muscarinic receptors (20) and cycloheximide induced amnesia is ameliorated by physostig mine, a choline esterase inhibitor (21) . These results indicate the possibility that the reduc tion of AChergic neuronal activity, such as in hibition of biosynthesis of receptor protein, is responsible for the cycloheximide-induced amnesia in the passive avoidance task. The subacute treatment with tacrine ameliorated the cycloheximide-induced amnesia. There fore, it is suggested that tacrine inhibited AChE activity in the brain and activated the AChergic neuronal system; and as a result, tacrine improved the cycloheximide-induced amnesia.
In the clinical state, it is well-known that there is a dysfunction of the basal magnocellu laris cholinergic system in Alzheimer's disease (22, 23) . A major AChergic input to the cere bral cortex originates in the BF which is known as the basalis magnocellularis or nu cleus basalis of Meynert in primates (24, 25) . The BF is an important region for memory function, since there are many reports describ ing BF lesion-induced amnesia (24, (26) (27) (28) . We have confirmed that ibotenic acid injection into the BF decreased ChAT activity in the fronto-parietal cortex and induced amnesia in the water maze task (29, 30) . In the present experiment, the BF lesion also decreased ChAT activity and impaired memory function in the passive avoidance and water maze tasks. Tacrine ameliorated the BF lesion-in duced amnesia in both the passive avoidance and water maze tasks, although it failed to ameliorate the decrease of ChAT activity. These facts suggested that the tacrine-induced amelioration of amnesia in the passive avoid ance and water maze tasks may be interpreted as an inhibition of AChE activity. Further more, tacrine may be effective for patients with Alzheimer's disease.
In this study, we attempted to examine whether subacute treatment with tacrine at low doses improves memory deficit or not, since previous reports have indicated that acute administration of tacrine at high doses (1 5 mg/kg) improves cognitive function (4 7). The present results showed that subacute treatment with tacrine for 2 3 weeks at a low dose (0.3 mg/kg) was the most effective for improving the BF lesion-induced amnesia. Since it is reported that tacrine produces some side effects such as hepatotoxicity, a subacute administration of tacrine at low doses may be useful for the therapy of Alzheimer's disease.
Tacrine inhibits AChE activity in a dose dependent manner in vitro (9) . However, the present results indicated that the dose (0.1-3 mg/kg)-response curves for tacrine were typi cally bell-shaped, especially in the BF lesion induced amnesia model, although it amelio rated cycloheximide-induced amnesia in a dose-dependent fashion (until 10 mg/kg). Tac rine (0.5 3 mg/kg) failed to ameliorate the amnesia in the water maze task. The discrep ancy of the dose-response curves may be due to the administration schedule and animal models: BF-lesioned animals were administer ed tacrine 3 times (3 weeks subacute adminis tration) more than cycloheximide-treated ani mals (1 week subacute administration). As we have reported, cycloheximide affects not only the AChergic neuronal system, but also the GABAergic (21), serotonergic (31) and opioidergic (32) neuronal systems, while ibotenic acid impairs only the AChergic neuronal system. Furthermore, there is a pos sibility that the bell-shaped dose-response curve is related to the toxicity of tacrine, since tacrine interacts with the N-methyl-D-aspar tate type of excitatory amino acid receptor as a mixed agonist/antagonist and produces neurotoxicity (33) .
Finally, our results are interesting in view of the recent reports demonstrating a rehabilita tion of memory function in Alzheimer patients by tacrine (10), lending additional empirical support for the use of tacrine and other choli nomimetics in clinical trials of treatment strategies for Alzheimer's disease.
